Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C

American Journal of Gastroenterology

Volumn 95, Issue 6, 2000, Pages 1524-1530

  Wong, John B ^d   Poynard, Thierry ^b   Ling, Mei Hsiu ^c   Albrecht, Janice K ^c   Pauker, Stephen G ^a  

^a Tupper Research Institute   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUCED DISEASE; FEMALE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TERATOGENESIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIFE EXPECTANCY; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0034124763     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00881-9     Document Type: Article

References (39)

1. Anonymous. National Institutes of Health Consensus Development Conference Panel Statement Management of hepatitis C . Hepatology. 26:(suppl 1):1997;2S-10S.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med. 341:1999;556-562.
3. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
4. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
5. Bennett W.G., Inoue Y., Beck J.R., et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 127:1997;855-865.
6. Kim W.R., Poterucha J.J., Hermans J.E., et al. Cost-effectiveness of 6, and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med. 127:1997;866-874.
7. Provenzale D., Lipscomb J. Cost-effectiveness Definitions and use in the gastroenterology literature . Am J Gastroenterol. 91:1996;1488-1493.
8. Wong J.B., Bennett W.G., Koff R.S., et al. Pre-treatment evaluation of chronic hepatitis C Risks, benefits and costs . JAMA. 280:1998;2088-2093.
9. Heckerling P.S., Verp M.S. Amniocentesis or chorionic villus sampling for prenatal genetic testing A decision analysis . J Clin Epidemiol. 44:1991;657-670.
10. Kuppermann M., Shiboski S., Feeny D., et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making. 17:1997;42-55.
11. Liu G., Franssen E., Fitch M.I., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
12. Wasserman Y. Physicians' Fee Reference 1995. 1995;Medical Publishers, Ltd, West Allis.
13. 1999 Drug Topics Red Book. 1999;Medical Economics Data, Inc, Montvale, NJ.
14. Anonymous. St. Anthony's DRG Guidebook 1995. Alexandria, VA: St. Anthony Publishing, 1996.
15. Ashraf T., Arnold S.B., Maxfield M. Cost-effectiveness of levonorgestrel subdermal implants. Comparison with other contraceptive methods available in the United States. J Reprod Med. 39:1994;791-798.
16. Consumer Price Index for All Urban Consumers, US City Average, Medical Care, 1982-98. 1999;Bureau of Labor Statistics, Washington, DC.
17. Gold M.R., Siegel J.E., Russell L.B., et al. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York.
18. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
20. Yano M., Kumada H., Kage M., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
21. Tong M.J., Blatt L.M., McHutchison J.G., et al. Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics A comparison . Hepatology. 26:1997;1640-1645.
22. Bonis P.A., Ioannidis J.P., Cappelleri J.C., et al. Correlation of biochemical response to interferon-α with histological improvement in hepatitis C A meta-analysis of diagnostic test characteristics . Hepatology. 26:1997;1035-1044.
23. Reichard O., Glaumann H., Fryden A., et al. Two-year biochemcial, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon α-2b treatment. Hepatology. 21:1995;918-922.
24. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement, and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C, and sustained response to interferon-alpha therapy. Ann Intern Med. 127:1997;875-881.
25. Lau D.T., Kleiner D.E., Ghany M.G., et al. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology. 28:1998;1121-1127.
26. Mor E., Kaspa R.T., Sheiner P., et al. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 129:1998;643-653.
27. Hoofnagle J.H. Hepatitis C The clinical spectrum of disease . Hepatology. 26:1997;15S-20S.
28. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
29. Mazzella G., Accogli E., Sottili S., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 24:1996;141-147.
30. Schalm S.W., Fattovich G., Brouwer J.T. Therapy of hepatitis C Patients with cirrhosis . Hepatology. 26:1997;128S-132S.
31. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-9.
32. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C Results of a large, prospective cohort study . Hepatology. 28:1998;1687-1695.
33. Sobesky R., Mathurin P., Charlotte F., et al. Modeling the impact of interferon α treatment on liver fibrosis progression in chronic hepatitis C A dynamic view. The Multivirc Group. Gastroenterology. 116:1999;378-386.
34. Bennett W.G., Pauker S.G., Davis G.L., et al. Modeling therapeutic benefit in the midst of uncertainty Therapy for hepatitis C . Dig Dis Sci. 41:1996;56S-62S.
35. Liang T.J. Combination therapy for hepatitis C infection. N Engl J Med. 339:1998;1549-1550.
36. Ellwein L.B., Drummond M.F. Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes. Int J Te A. 12:1996;691-697.
37. Drummond M.F., Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Te A. 7:1991;561-573.
38. Wright J.C., Weinstein M.C. Gains in life expectancy from medical interventions Standardizing data on outcomes . N Engl J Med. 339:1998;380-386.
39. Tsevat J., Weinstein M.C., Williams L.W., et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 83:1991;1194-1201.